Jeito Capital raises greater than $1.2 billion for brand new biopharmaceutical investments
International impartial personal fairness fund Jeito Capital has closed its second fund, Jeito II, exceeding its €1 billion ($1.2 billion) goal, reaching an vital new milestone for European Biopharma investing.
This milestone will increase Jeito’s property beneath administration to €1.6 billion, following the closure of Jeito I for €534 million in 2021.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra info
Constructing on the Jeito I initiative, Jeito II will put money into 15 to twenty clinical-stage biopharmaceutical corporations, primarily in Europe, to develop breakthrough therapies concentrating on severe illnesses with excessive unmet medical wants.
This fundraising will allow Jeito to extend the typical dimension of future investments in portfolio corporations to €150 million, and allow them to speed up their progress in the direction of superior medical improvement.
Jeito II has already deployed capital in corporations targeted on therapeutic areas reminiscent of autoimmune, cardiometabolic and inflammatory illnesses, in addition to weight problems, oncology and reproductive medication.
Jeito’s funding method emphasizes high-potential corporations creating breakthrough therapies.
Jeito II obtained help from traders in Asia, Europe and North America, together with sovereign wealth funds, company entities, banks and household places of work.
Founder and CEO of Jeito Capital, Dr. Rafaèle Tordjman, stated: “The closing of Jeito II for multiple billion euros represents an important milestone for our firm. This file fundraising is a collective success and displays the dedication and experience of the whole Jeito crew, the expertise of the portfolio firm managers and the arrogance of our traders.
“We wish to thank all of them for his or her arduous work, dedication and help. Additionally it is a robust sign for the European Biopharma ecosystem, demonstrating the rising perception that European corporations can drive main therapeutic innovation and vital financial advantages with the fitting entry to monetary and strategic assets.”
